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To better understand the diagnostic and predictive
performance of urinary biomarkers of kidney injury, we
evaluated c-glutamyltranspeptidase (GGT), alkaline
phosphatase (AP), neutrophil-gelatinase-associated lipocalin
(NGAL), cystatin C (CysC), kidney injury molecule-1 (KIM-1),
and interleukin-18 (IL-18) in a prospective observational
study of 529 patients in 2 general intensive care units (ICUs).
Comparisons were made using the area under the receiver
operator characteristic curve (AUC) for diagnosis or
prediction of acute kidney injury (AKI), dialysis, or death,
and reassessed after patient stratification by baseline renal
function (estimated glomerular filtration rate, eGFR) and time
after renal insult. On ICU entry, no biomarker had an AUC
above 0.7 in the diagnosis or prediction of AKI. Several
biomarkers (NGAL, CysC, and IL-18) predicted dialysis
(AUC over 0.7), and all except KIM-1 predicted death at 7 days
(AUC between 0.61 and 0.69). Performance was improved
by stratification for eGFR or time or both. With eGFR
o60ml/min, CysC and KIM-1 had AUCs of 0.69 and 0.73,
respectively, within 6h of injury, and between 12 and 36h,
CysC (0.88), NGAL (0.85), and IL-18 (0.94) had utility. With
eGFR 460ml/min, GGT (0.73), CysC (0.68), and NGAL (0.68)
had the highest AUCs within 6h of injury, and between 6 and
12h, all AUCs except AP were between 0.68 and 0.78. Beyond
12h, NGAL (0.71) and KIM-1 (0.66) performed best. Thus,
the duration of injury and baseline renal function should
be considered in evaluating biomarker performance to
diagnose AKI.
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The unavoidable delay in the diagnosis of acute kidney
injury (AKI) resulting from the use of plasma creatinine
(PCr) has stimulated development of new urinary and
plasma biomarkers.1–4 These biomarkers have been validated
by post hoc evaluation of prospectively studied patient
cohorts after stratification into those who developed AKI
or other conditions,5 or in relatively homogeneous popula-
tions, such as after cardiopulmonary bypass.6 Biomarker
performance is measured by assessing diagnostic or pre-
dictive performance with respect to a functional outcome
based on PCr.7 This makes the diagnosis of kidney cell-
specific injury subject to the definition and classification of
AKI8–10 and further subject to the vagaries of determining
baseline renal function in the large proportion of patients
who present without a previous recorded PCr.11–14 Although
discovery has been driven by the success of individual
biomarkers in homogeneous populations, performance is
poorer in more heterogeneous populations when time of
renal injury is poorly defined.15,16 The same biomarkers
perform differently under different conditions,17 including
differences in baseline glomerular filtration rate (GFR).18 The
expectation that a panel of biomarkers could provide higher
specificity and sensitivity for AKI in a heterogeneous
population requires understanding of biomarker behavior
under these conditions.
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In the largest biomarker study to date, we recently
demonstrated that a urinary biomarker, the combination
product of g-glutamyltranspeptidase (GGT) and alkaline
phosphatase (AP), facilitated randomization to intervention
within 6.3±4.2 h (mean±s.d.) of entry to the intensive care
unit (ICU) in the EARLYARF (Early Intervention in Acute
Renal Failure) trial.16 Although the diagnosis of AKI was
rapid compared with the usual 48–72 h delay based on
creatinine-based methods, the transient increase in this
biomarker combination compromised effective triaging to
early intervention in this population with a heterogeneous
duration of renal injury.16 Stratification for time after
presumed injury improved biomarker performance.16 In
the same study, we prospectively acquired urine and plasma
for other novel biomarkers, including neutrophil-gelatinase-
associated lipocalin (NGAL), kidney injury molecule
(KIM)-1, and interleukin (IL)-18, each reported to have a
high predictive value for AKI.19 We also analyzed urine and
plasma for cystatin C (CysC) and reported these results
separately.20,21
We now report the first head-to-head comparison of these
novel biomarkers in a heterogeneous high-risk population as
diagnostic and predictive markers of AKI, need for dialysis,
and prediction of mortality at 7 days in patients stratified
both for time elapsed after renal insult and for GFR at time of
ICU admission.
RESULTS
Of 529 patients recruited, 1 withdrew all data leaving 528
patients for analysis. Patient characteristics and biomarker
concentrations on entry are shown in Tables 1a and b.
Biomarker correlations
Urinary biomarker concentrations were moderately corre-
lated with one another on entry to the ICU (Table 2), with
the strongest correlations between the two brush border
enzymes (GGT and AP, r¼ 0.66) and between two freely
filtered analytes (NGAL and CysC, r¼ 0.60).
Biomarker performance
AKI diagnosis. All biomarkers except AP were diagnostic
of AKI on entry to the ICU with low sensitivity (areas under
the receiver operator characteristic curve, AUCs from 0.59 to
0.67, sensitivity from 0.27 to 0.40, Table 3). Figure 1a high-
lights the overlap in data from all biomarkers. IL-18 and CysC
displayed the greatest separation of median biomarker
concentrations between patients with or without AKI on entry.
Prediction of dialysis and death. CysC, IL-18, and NGAL
were the strongest predictors of dialysis (AUC 40.70). In
patients without AKI on entry, AP, NGAL, and IL-18 were the
strongest predictors of dialysis (Table 4). All biomarkers
except KIM-1 were moderately predictive of death within
7 days (AUC 40.60, Table 3), especially IL-18 (AUC¼ 0.68).
GGT, CysC, NGAL, and IL-18 remained independently
associated with mortality after adjusting for sex, age, weight,
baseline estimated GFR (eGFR), Acute Physiology and
Chronic Health Evaluation, and Sequential Organ Failure
Assessment with odds ratios for a 10-fold increase in
concentration of 2.37 (1.21–4.64), 1.53 (1.18–2.00), 1.66
(1.19–2.32), and 1.24 (1.08–1.42), respectively.
Table 1a | Patient demographics (total cohort, n=528)
Characteristics
Age (years), mean±s.d. 60±17
Female % (n) 39.8 (210)
Weight (kg), mean±s.d. 80±19
APACHE II score, mean±s.d. 18±6.4
SOFA score, mean±s.d. 6.3±2.8
Primary diagnosis (%) (n)
Abdominal aortic aneurysm rupture and repair 4.5 (24)
Abdominal surgery or inflammation 10.2 (54)
Burns 0.9 (5)
Cardiac arrest or failure 11.9 (63)
Cardiac surgery 17.8 (94)
Collapse, cause unknown 0.6 (3)
Neurological surgery, injury, or seizure or hemorrhage 14.0 (74)
Other 0.6 (3)
Pulmonary or thoracic surgery or failure 12.1 (64)
Sepsis 19.1 (101)
Trauma 8.1 (43)
Outcomes (%) (n)
AKIN on entry 27.8 (147)
AKIN48 15.5 (82)
RIFLE24 5.1 (27)
Dialysis within 7 days 3.6 (19)
Died within 7 days 10.2 (54)
Abbreviations: AKI, acute kidney injury; AKIN48, AKI within 48 h; APACHE II, Acute
Physiology and Chronic Health Evaluation; ICU, intensive care unit; SOFA, Sequential
Organ Failure Assessment.
Table modified from the study by Endre et al., 2010.16
AKIN on entry: X0.3mg/dl or X50% increase in plasma creatinine from baseline
on entry to the ICU.
AKIN48: Not AKIN on entry and X0.3mg/dl or X50% increase in plasma creatinine
from baseline within B48 h.
RIFLE24: Not AKIN on entry and X50% increase in plasma creatinine sustained for
X24 h within 7 days.
Table 1b | Urinary biomarker concentrations on entry
N Mean±s.d. Median (IQR) Min Max
GGT (Units/l)/mmol/l Cr 526 28±55 13 (7–25) 1.9 923
AP (Units/l)/mmol/l Cr 526 1.7±4.1 0.89 (0.46–1.8) 0.00025 74.8
CysC (mg/l)/mmol/l Cr 522 0.40±1.1 0.016 (0.001–0.17) 0.0001 9.3
NGAL (ng/ml)/mmol/l Cr 487 140±410 8.0 (2.5–41) 0.0001 3000
IL-18 (pg/ml)/mmol/l Cr 523 73±340 0.001 (0.001–36)a 0.0001 3100
KIM-1 (pg/ml)/mmol/l Cr 524 300±1400 86 (37–210) 0.56 2800
Abbreviations: AP, alkaline phosphatase; Cr, creatinine; CysC, cystatin C; GGT,
g-glutamyltranspeptidase; IL-18, interleukin-18; IQR, interquartile range; KIM-1,
kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin.
aSee distribution in Figure 1.
Table 2 | Correlations among urinary biomarkers on entry
Spearman’s rho AP/uCr CysC/uCr NGAL/uCr IL-18/uCr KIM-1/uCr
GGT/uCr 0.66 0.24 0.33 0.33 0.25
AP/uCr 0.17 0.26 0.20 0.19
CysC/uCr 0.60 0.52 0.39
NGAL/uCr 0.41 0.41
IL-18/uCr 0.32
Abbreviations: AP, alkaline phosphatase; CysC, cystatin C; GGT, g-glutamyl-
transpeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL,
neutrophil-gelatinase-associated lipocalin; uCr, urinary creatinine.
All correlations Po0.0001.
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AKI in patients without AKI on admission. No biomarker
predicted AKI within 48 h (AKIN48) (Table 4). Only IL-18
predicted more severe AKI (RIFLE24: aX50% increase in
creatinine sustained for X24 hours within 7 days) with an
AUC 40.7. Figure 1b highlights that even with this more
severe definition of AKI, considerable scatter remained.
Timing
After stratification by time after renal insult, all biomarkers
except AP showed enhanced performance (Table 5). The
results reflect both the time course of the individual
biomarkers and the severity of insult. The effect of biomarker
time course was further assessed by examining the predictive
value for AKI within 48 h of entry (AKIN48, Table 5). The
predictive value was greatest (AUC 40.7) for GGT 6–12 h
after injury, and for CysC and IL-18 beyond 36 h after injury.
Function
When biomarker concentration was stratified by baseline
eGFR, there was a marginal improvement in the diagnostic
performance with CysC and KIM-1 having AUC X0.7 in
the subcohort with eGFR o60 ml/min and CysC and
NGAL having AUC 40.7 in the subcohort with eGFR
90–120 ml/min (Table 6). Predictive performance remained
poor, except where eGFR o60 ml/min; here, GGT had the
highest AUC (0.79).
Timing and function
Stratifying biomarker concentration according to time after
renal insult may explain the time dependence of some
biomarker performance (Figure 2). A decline in GGT and AP
concentrations with time suggests that these pre-formed
brush border enzymes are excreted in diminishing amounts
after injury. The remaining biomarkers demonstrated
increasing concentrations with time in AKI patients con-
sistent with induction, although at different rates. IL-18,
CysC, and KIM-1 exhibited a brief increase, whereas the
increase in NGAL was more sustained. CysC continued to
increase, whereas IL-18 and NGAL had a possible biphasic
pattern which may be explained by ongoing injury especially
in patients with sepsis; these entered the ICU later after insult
than did other patients (29 (interquartile range 16–82) h for
sepsis versus 6.2 (4.2–18) h, Po0.0001).
The effect of stratifying biomarker concentration according
to both time after renal insult and baseline eGFR is summ-
arized in the contour plots of AUC for AKI on entry for each
Table 3 | ROC–AUC evaluation of biomarker performance on entry a
AUC P-value Upper quartile threshold Sensitivityb Specificityb PPVb NPVb
Diagnosis of AKI (n=147)
GGT/uCr 0.59 (0.54–0.65)c 0.0009 25 (Units/l)/mmol/l Cr 0.37 (0.30–0.45) 0.80 (0.76–0.84) 0.42 (0.34–0.50) 0.76 (0.72–0.80)
AP/uCr 0.45 (0.40–0.50)d 0.07 1.8 (Units/l)/mmol/l Cr 0.27 (0.20–0.34) 0.76 (0.72–0.80) 0.31 (0.23–0.38) 0.73 (0.69–0.77)
CysC/uCr 0.67 (0.62–0.73) o0.0001 0.17 (mg/l)/mmol/l Cr 0.40 (0.32–0.48) 0.81 (0.77–0.85) 0.45 (0.36–0.53) 0.78 (0.73–0.82)
NGAL/uCr 0.66 (0.60–0.72) o0.0001 41 (ng/ml)/mmol/l Cr 0.40 (0.31–0.48) 0.80 (0.76–0.84) 0.43 (0.34–0.51) 0.78 (0.74–0.83)
IL-18/uCr 0.62 (0.56–0.67)e o0.0001 36 (pg/ml)/mmol/l Cr 0.34 (0.26–0.41) 0.78 (0.74–0.82) 0.37 (0.29–0.46) 0.75 (0.71–0.80)
KIM-1/uCr 0.66 (0.61–0.72) o0.0001 210 (pg/ml)/mmol/l Cr 0.40 (0.32–0.48) 0.81 (0.77–0.85) 0.45 (0.37–0.54) 0.78 (0.73–0.82)
Prediction of dialysis in 7 days (n=19)
GGT/uCr 0.60 (0.46–0.74)f 0.15 25 (Units/l)/mmol/l Cr 0.28 (0.07–0.48) 0.75 (0.71–0.79) 0.04 (0.01–0.07) 0.97 (0.95–0.98)
AP/uCr 0.63 (0.49–0.77) 0.07 1.8 (Units/l)/mmol/l Cr 0.61 (0.39–0.84) 0.76 (0.73–0.80) 0.08 (0.04–0.13) 0.98 (0.97–1.00)
CysC/uCr 0.71 (0.57–0.84) 0.003 0.17 (mg/l)/mmol/l Cr 0.56 (0.33–0.79) 0.76 (0.72–0.80) 0.08 (0.03–0.12) 0.98 (0.97–0.99)
NGAL/uCr 0.79 (0.65–0.94) o0.0001 41 (ng/ml)/mmol/l Cr 0.64 (0.39–0.89) 0.76 (0.72–0.80) 0.07 (0.03–0.12) 0.99 (0.97–1.00)
IL-18/uCr 0.73 (0.59–0.86) 0.001 36 (pg/ml)/mmol/l Cr 0.67 (0.45–0.88) 0.76 (0.73–0.80) 0.09 (0.04–0.14) 0.98 (0.97–1.00)
KIM-1/uCr 0.62 (0.48–0.76)g 0.10 210 (pg/ml)/mmol/l Cr 0.44 (0.21–0.67) 0.76 (0.72–0.79) 0.06 (0.02–0.10) 0.97 (0.96–0.99)
Prediction of death in 7 days (n=53h)
GGT/uCr 0.65 (0.56–0.73) 0.003 25 (Units/l)/mmol/l Cr 0.42 (0.28–0.55) 0.77 (0.73–0.81) 0.17 (0.10–0.23) 0.92 (0.89–0.95)
AP/uCr 0.61 (0.53–0.70) 0.008 1.8 (Units/l)/mmol/l Cr 0.43 (0.30–0.57) 0.77 (0.73–0.81) 0.18 (0.11–0.24) 0.92 (0.90–0.95)
CysC/uCr 0.66 (0.58–0.75) 0.0001 0.17 (mg/l)/mmol/l Cr 0.42 (0.28–0.55) 0.77 (0.73–0.81) 0.17 (0.10–0.23) 0.92 (0.89–0.95)
NGAL/uCr 0.66 (0.57–0.74) 0.0002 41 (ng/ml)/mmol/l Cr 0.47 (0.33–0.61) 0.78 (0.74–0.81) 0.20 (0.13–0.27) 0.93 (0.90–0.95)
IL-18/uCr 0.68 (0.60–0.76) o0.0001 36 pg/ml)/mmol/l Cr 0.55 (0.41–0.68) 0.78 (0.75–0.82) 0.22 (0.15–0.29) 0.94 (0.92–0.96)
KIM-1/uCr 0.56 (0.47–0.64)i 0.17 210 (pg/ml)/mmol/l Cr 0.34 (0.21–0.47) 0.76 (0.72–0.80) 0.14 (0.08–0.20) 0.91 (0.88–0.94)
Abbreviations: AKI, acute kidney injury; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic (ROC) curve; CysC, cystatin C; GGT,
g-glutamyltranspeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; NPV, negative predictive value;
PPV, positive predictive value; uCr, urinary creatinine.
an=528. The 95% confidence intervals for all values are shown in brackets.
bCalculated using the threshold value of the upper quartile for each biomarker as the cutoff. For the model, the upper quartile shown is the upper quartile of the probability
calculated by the model of having the event.
cAKI: significantly lower than the AUCs for CysC/uCr and NGAL/uCr.
dAKI: significantly lower than all the other biomarkers.
eAKI: significantly lower than the AUC for CysC/uCr.
fDialysis: significantly lower than the AUC for NGAL/uCr.
gDialysis: significantly lower than the AUC for IL-18/uCr.
hOne patient who died was anuric on entry and no urinary biomarkers data were obtained; therefore, n=53 not n=54.
iDeath: significantly lower than the AUC for CysC/uCr, NGAL/uCr, and IL-18/uCr.
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biomarker in Figure 3. Individual values are shown for
stratification into only two groups (o60 and X60 ml/min) in
Table 7 and for all eGFR groups in Appendix Table 1.
The data highlight that the diagnostic performance of each
biomarker depends on both time after insult and baseline
renal function at entry to the ICU. AP did not perform well at
any time (AUC always o0.70). In patients with chronic
kidney disease (eGFR o60 ml/min) GGT, CysC, NGAL, and
IL-18 had AUC X0.85, but only between 12 and 36 h after
renal insult. With eGFR X60 ml/min, GGT detected AKI
with AUC X0.73, IL-18, with AUC X0.63, and AP with AUC
X0.62, for up to 12 h after insult. NGAL, with AUC X0.68,
CysC, with AUC X0.65, and KIM-1, with AUC X0.62,
detected AKI for up to 36 h.
DISCUSSION
This comparison of six renal injury biomarkers of AKI
available at the time of study initiation in 2005 highlights
several issues critical to the successful utilization of injury
biomarkers. For prediction of dialysis, NGAL, CysC, and
IL-18 yielded AUC values 40.7, and all biomarkers had very
high negative predictive values (X0.97). All biomarkers
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Figure 1 | Scatter plot of all six urinary biomarkers according to the AKI status of the patient. (a) On entry to the ICU (AKI on entry)
and (b) for those not AKI on entry, according to RIFLE24. It must be noted that for IL-18/uCr, the median line for the ‘no AKI’ group
lies within the subthreshold values. AKI, acute kidney injury; AP, alkaline phosphatase; CysC, cystatin C; GGT, g-glutamyltranspeptidase;
ICU, intensive care unit; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary
creatinine.
Table 4 | AUCs for prediction of AKI and dialysis in patients without AKI on entrya
AKIN48 (n=82) P RIFLE24 (n=27) P Dialysis (n=12) P
GGT/uCr 0.57 (0.50–0.64) 0.058 0.61 (0.49–0.73) 0.062 0.63 (0.46–0.81) 0.13
AP/uCr 0.56 (0.49–0.63) 0.11 0.64 (0.52–0.76) 0.018 0.72 (0.55–0.88) 0.010
CysC/uCr 0.55 (0.48–0.62) 0.18 0.63 (0.51–0.74) 0.004 0.66 (0.49–0.83) 0.070
NGAL/uCr 0.55 (0.48–0.63) 0.17 0.68 (0.56–0.80) 0.003 0.78 (0.61–0.95) 0.001
IL-18/uCr 0.55 (0.47–0.62) 0.21 0.72 (0.61–0.83)b o0.0001 0.70 (0.53–0.87) 0.020
KIM-1/uCr 0.55 (0.47–0.62) 0.21 0.64 (0.52–0.76) 0.018 0.63 (0.45–0.80) 0.15
Abbreviations: AKI, acute kidney injury; AKIN48, AKI within 48 h; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C;
GGT, g-glutamyltranspeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary creatinine.
an=381.
bRIFLE24: significantly higher than the AUC for CysC/uCr.
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Table 5 | AUCs for AKI stratified according to time after insult
Time from insult o6h (n=178 [37]) 6 to o12h (n=94 [20]) 12 to o36h (n=115 [48]) X36h (n=107 [39])
Diagnosis of AKI (AKI on entry)a
GGT/uCr 0.70 (0.60–0.80) 0.67 (0.52–0.81) 0.61 (0.50–0.71) 0.52 (0.40–0.63)
AP/uCr 0.60 (0.49–0.71)b 0.49 (0.34–0.63)c 0.41 (0.30–0.51)d 0.39 (0.29–0.50)e
CysC/uCr 0.67 (0.57–0.78) 0.75 (0.62–0.88) 0.68 (0.57–0.78) 0.52 (0.41–0.64)
NGAL/uCr 0.66 (0.55–0.77) 0.65 (0.50–0.80) 0.71 (0.61–0.82)f 0.60 (0.48–0.72)
IL-18/uCr 0.62 (0.52–0.73) 0.67 (0.53–0.81) 0.64 (0.53–0.74) 0.51 (0.39–0.62)
KIM-1/uCr 0.62 (0.52–0.73) 0.66 (0.52–0.81) 0.67 (0.56–0.77) 0.61 (0.49–0.72)
Prediction of AKI (AKIN48)g o6h (n=141 [32]) 6 to o12h (n=74 [15]) 12 to o36h (n=67 [11]) X36h (n=68 [18])
GGT/uCr 0.50 (0.39–0.62) 0.71 (0.55–0.87)h 0.58 (0.39–0.77) 0.47 (0.31–0.62)
AP/uCr 0.59 (0.48–0.71) 0.63 (0.46–0.79) 0.42 (0.25–0.60) 0.47 (0.31–0.62)
CysC/uCr 0.48 (0.37–0.59) 0.61 (0.45–0.78) 0.48 (0.29–0.67) 0.73 (0.59–0.88)i
NGAL/uCr 0.53 (0.41–0.65) 0.49 (0.31–0.67) 0.55 (0.35–0.75) 0.60 (0.44–0.77)j
IL-18/uCr 0.38 (0.28–0.49)k 0.60 (0.43–0.77) 0.47 (0.28–0.65) 0.75 (0.60–0.89)l
KIM-1/uCr 0.54 (0.43–0.66) 0.57 (0.40–0.74) 0.47 (0.29–0.66) 0.48 (0.32–0.64)
Abbreviations: AKI, acute kidney injury; AKIN48, AKI within 48 h; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C;
GGT, g-glutamyltranspeptidase; ICU, intensive care unit; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary
creatinine.
The number in square brackets is the number of patients with AKI.
aAKI on entry: cohort: all patients on entry to the ICU (n=528).
bo6 h: significantly lower than the AUC for GGT/uCr.
c6 to o12 h: significantly lower than the AUCs for GGT/uCr, CysC/uCr, and KIM-1/uCr.
d12 to o36 h: significantly lower than the AUCs for all other biomarkers.
eX36 h: significantly lower than the AUCs for GGT/uCr, NGAL/uCr, and KIM-1/uCr.
fX36 h: significantly higher than the AUCs for GGT/uCr and AP/uCr.
gAKIN48: all patients on entry to the ICU without AKI on entry (n=381).
h6 to o12 h: significantly higher than the AUC for NGAL/uCr.
iX36 h: significantly higher than the AUCs for all other biomarkers, except IL-18/uCr.
jX36 h: significantly higher than the AUCs for all other biomarkers, except CysC/uCr.
ko6 h: significantly lower than the AUCs for all other biomarkers, except CysC/uCr.
lX36 h: significantly higher than the AUCs for GGT/uCr.
Table 6 | AUCs for AKI stratified according to eGFR
eGFR
o60ml/min
(n=96 [27])
60 to o90ml/min
(n=172 [56])
90 to o120ml/min
(n=162 [34])
X120ml/min
(n=96 [30])
Diagnosis of AKI (AKI on entry)a
GGT/uCr 0.46 (0.33–0.59) 0.60 (0.50–0.69) 0.66 (0.55–0.76) 0.62 (0.49–0.74)
AP/uCr 0.37 (0.25–0.49) 0.46 (0.37–0.55)b 0.45 (0.35–0.56)b 0.51 (0.38–0.63)c
CysC/uCr 0.72 (0.60–0.84)d 0.60 (0.51–0.70) 0.75 (0.65–0.85)e 0.66 (0.54–0.79)
NGAL/uCr 0.64 (0.50–0.78)d 0.64 (0.54–0.73) 0.70 (0.59–0.81) 0.69 (0.56–0.81)f
IL-18/uCr 0.65 (0.52–0.77)d 0.60 (0.51–0.69) 0.67 (0.56–0.78) 0.56 (0.43–0.68)
KIM-1/uCr 0.70 (0.58–0.82)d 0.68 (0.59–0.77) 0.63 (0.52–0.74) 0.61 (0.49–0.74)
Prediction of AKI
(AKIN48)g
o60ml/min
(n=69 [20])
60 to o90ml/min
(n=116 [25])
90 to o120ml/min
(n=128 [26])
X120ml/min
(n=66 [11])
GGT/uCr 0.79 (0.66–0.92) 0.48 (0.35–0.60) 0.50 (0.37–0.62) 0.56 (0.36–0.75)h
AP/uCr 0.71 (0.56–0.85) 0.48 (0.35–0.60) 0.54 (0.41–0.66) 0.55 (0.36–0.74)
CysC/uCr 0.64 (0.49–0.79) 0.54 (0.41–0.67) 0.58 (0.45–0.71) 0.35 (0.18–0.51)
NGAL/uCr 0.71 (0.56–0.87) 0.53 (0.39–0.67) 0.53 (0.41–0.66) 0.44 (0.25–0.63)
IL-18/uCr 0.65 (0.50–0.80) 0.48 (0.35–0.60) 0.57 (0.45–0.70) 0.49 (0.30–0.67)
KIM-1/uCr 0.66 (0.52–0.81) 0.44 (0.32–0.56) 0.65 (0.52–0.77) 0.37 (0.20–0.54)
Abbreviations: AKI, acute kidney injury; AKIN48, AKI within 48 h; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C;
eGFR, estimated glomerular filtration rate; GGT, g-glutamyltranspeptidase; ICU, intensive care unit; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-
gelatinase-associated lipocalin; uCr, urinary creatinine.
The number in square brackets is the number of patients with AKI.
aAKI on entry: cohort: all patients on entry to the ICU (n=528).
b60 to o90ml/min and 90 to o120ml/min: significantly lower than the AUCs for all other biomarkers.
cX120ml/min: significantly lower than the AUCs for GGT/uCr, CysC/uCr, and NGAL/uCr.
do60ml/min: significantly higher than the AUCs for GGT/uCr and AP/uCr.
e90 to o120ml/min: significantly higher than the AUCs for AP/uCr and KIM-1/uCr.
fX120ml/min: significantly higher than the AUCs for AP/uCr and IL-18/uCr.
gAKIN48: cohort: all patients on entry to the ICU without AKI on entry (n=381).
hX120ml/min: significantly higher than the AUCs for CysC/uCr and KIM-1/uCr.
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except KIM-1 showed values between 0.6 and 0.7, for
prediction of death within 7 days.
However, with AUCs o0.7 on entry to the ICU, all
urinary biomarkers had limited efficacy in the diagnosis or
prediction of AKI. The results imply that it is difficult to
choose a cutoff that did not result in high numbers of
false positives and false negatives (the scatter in Figure 1 must
be noted). These low AUC values contrast with high
AUCs for AKI found with many of the same biomarkers
in more homogeneous cohorts, such as post-cardiac surgery
patients.6,22,23 However, direct comparisons with other
studies are complicated by the different definitions of AKI
used. For example, one study of urinary NGAL in the
emergency department yielded an AUC of 0.948 (0.881–1)
for AKI,5 which is much higher than that observed in this
study. Several factors may account for this difference: the
measurements were always closer to the time of insult than
in this study, the emergency department cohort differed
from the ICU cohort (for example, only 6.1% of emergency
department patients entered the ICU), and the definition of
AKI used (a 1.5-fold increase in creatinine from baseline that
lasted for 3 days despite volume resuscitation) was more
restrictive than that used in our study, resulting in only 30
out of 635 patients being diagnosed with AKI. The study
most comparable with this study was one of 451 ICU patients
of whom 86 developed AKI within 48 h (AKIN definition).24
In that study, NGAL and IL-18 showed similar poor
performance for predicting AKI (AUCs of 0.71: 95%
confidence interval: 0.63–0.78 and 0.62: 95% confidence
interval: 0.54–0.69, respectively). An improvement in the
AUC for IL-18 was observed in a sensitivity analysis of
patients with an eGFR X75 ml/min.
Superficially, the poor performance of the biomarkers
suggests that indiscriminate application on all admissions to
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Figure 2 |Time course of each urinary biomarker from putative insult. (a) GGT, g-glutamyltranspeptidase, (b) AP, alkaline phosphatase,
(c) CysC, cystatin C, (d) NGAL, neutrophil-gelatinase-associated lipocalin, (e) IL-18, interleukin-18, and (f) KIM-1, kidney injury molecule-1. All
patients are included. AKI is AKI on entry or AKIN48 (AKI at any time within 48 h of entry to the ICU). Values shown are mean±s.e.m. There
are approximately 50 measures at each time point for the AKI group. AKI, acute kidney injury; ICU, intensive care unit.
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an ICU may be futile. However, the importance of this study
rests not so much in the absolute AUCs but in the
comparative performance of the biomarkers in detecting
AKI and in identifying parameters, which affect biomarker
performance. Biomarker performance in diagnosing AKI
improved after stratification for time after renal insult for up
to 12 h; NGAL had a significantly higher AUC between
12 and 36 h (0.71). Only GGT was an early predictor of
future AKI diagnosis soon after insult (6–12 h). These
differences reflect the time course of each biomarker after
injury. The brief period of GGT increase (Figure 2) suggests
that only pre-formed enzyme appears in the urine, and is
rapidly depleted, leaving a narrow window of opportunity for
early diagnosis.16 The progressive increases in other bio-
markers mimic known induction after injury, except for
CysC. A progressive increase in CysC presumably reflects
increasing proximal tubular injury and impaired reabsorp-
tion. The results highlight the distinction between pre-
formed biomarkers represented by tubular enzymes such as
GGT and biomarkers with expression induced by renal injury,
such as NGAL, IL-18, and KIM-1. Although the duration of
release may vary,23 clearance of pre-formed biomarkers
appears to be well circumscribed in time compared with
induced markers.
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Figure 3 | Schematic interpretation of biomarker diagnostic performance, stratified for both time after renal insult and for baseline
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on entry to the ICU, illustrating that the diagnostic performance of a biomarker depends on both the individual’s normal renal status (eGFR)
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The performance of all six biomarkers depended on
baseline eGFR. Additional stratification for time after insult
(Figure 3) demonstrated that GGT, CysC, IL-18, NGAL, and
KIM-1 performance was enhanced early (up to 12 h after
injury) in patients with eGFR X60 ml/min. For patients with
pre-existing renal dysfunction (eGFR o60 ml/min), the
optimal detection window was delayed to between 12 and
36 h. Prediction of AKI was similarly time and function
dependent, and suggested that optimum predictive perfor-
mance occurred in patients with eGFR o60 ml/min
(Appendix Table 2). Nevertheless, the smaller numbers
available for predictive performance after stratification and
exclusion of patients with AKI on entry suggests caution in
assessing the predictive performance of individual biomarkers.
Stratification by baseline GFR was predicted to enhance
the diagnostic utility of NGAL, as the magnitude of injury
(reflected by NGAL generation) should be greater in those
developing AKI starting with normal baseline GFR.18
However, in a study of 426 cardiac surgery patients, there
was no relationship between post-operative urinary NGAL
concentration and development of AKI in patients with
baseline eGFR o60 ml/min.18 A relationship was observed
when eGFR was 460 ml/min and NGAL performance was
best for a baseline eGFR of 90–120 ml/min. As urinary
creatinine data were unavailable, unaccounted variations in
urine output may have influenced NGAL concentration. The
results are consistent with this study and together highlight
that the biomarker utility window is later and more limited
in subjects with pre-existing renal dysfunction.
The poorer performance of biomarkers in patients with
eGFR o60 ml/min could result from impaired biomarker
excretion in CKD, or because more variable excretion occurs
in CKD. For example, if NGAL excretion is already increased
in CKD,25 this generates more ‘noise’ against which the
biomarker signal must be measured.
The results suggest that developing a panel of biomarkers
for AKI will be complex. Simple logic or logistic regression
models to construct a panel of biomarkers are unlikely to
improve on the performance of a single biomarker unless
timing and baseline renal function are accounted for. If both
time of insult and baseline GFR are known, an optimal
‘phase-specific’ biomarker could be chosen for the time
elapsed.26 However, if time from insult or baseline renal
function is unknown, multiple and repeated biomarker
measurements will be required to detect (and time) AKI.
The outcome of this analysis depends critically on a
creatinine-based definition of AKI. Almost half the patients
had no baseline creatinine estimate, and in these, the
diagnosis of AKI could only be made retrospectively by
using a hierarchy of measured values obtained either before
admission or from the lowest post-admission or ICU value.
By using only measured creatinine, we avoided formulaic
estimates of baseline creatinine, which produce systematic
errors in AKI diagnosis.11,13,14,27 This highlights the potential
futility of validating a diagnostic test for injury against an
imperfect surrogate marker of change in filtration.7
The analysis is also based on biomarkers indexed to
urinary creatinine to account for variations in water
reabsorption. It has been suggested that during dynamic
changes in GFR, this process may lead to either over-
estimation or underestimation of the indexed biomarker
concentrations depending on clinical context.28 We have also
analyzed our data (Tables 1b–7) for the absolute biomarker
concentrations (not indexed to urinary creatinine) and found
that although there were small changes in AUC, the trends
and associations with timing and baseline GFR discussed in
this study remain unchanged. These data are presented in
Supplementary Tables S1b–7 online.
The inclusion of all patients, including those in the
randomized control arm who received erythropoietin (EPO),
Table 7 | AUCs for diagnosis of AKI according to time after insult and eGFR
o6h 6 to o12h 12 to o36h X36h
eGFR (ml/min) Time from insult n=24 [3] n=40 [4] n=12 [8] n=20 [12]
o60 GGT/uCr 0.41 (0.08–0.75) 0.26 (0.04–0.49) 0.91 (0.73–1) 0.48 (0.21–0.74)
AP/uCr 0.17 (0–0.38) 0.19 (0.01–0.37) 0.62 (0.29–0.96) 0.40 (0.13–0.66)
CysC/uCr 0.69 (0.34–1) 0.65 (0.35–0.96) 0.88 (0.67–1) 0.44 (0.17–0.70)
NGAL/uCr 0.45 (0.10–0.80) 0.39 (0.07–0.7) 0.85 (0.58–1) 0.58 (0.32–0.84)
IL-18/uCr 0.62 (0.26–0.98) 0.61 (0.30–0.92) 0.94 (0.80–1) 0.41 (0.14–0.67)
KIM-1/uCr 0.73 (0.39–1) 0.43 (0.14–0.72) 0.66 (0.33–0.98) 0.65 (0.40–0.89)
n=153 [34] n=83 [17] n=104 [41] n=90 [28]
X60 GGT/uCr 0.73 (0.62–0.83) 0.78 (0.64–0.92) 0.57 (0.45–0.68) 0.55 (0.42–0.68)
AP/uCr 0.64 (0.53–0.75) 0.62 (0.46–0.77) 0.37 (0.26–0.48) 0.4 (0.28–0.52)
CysC/uCr 0.68 (0.57–0.79) 0.77 (0.63–0.91) 0.65 (0.54–0.76) 0.53 (0.40–0.66)
NGAL/uCr 0.68 (0.57–0.80) 0.69 (0.52–0.85) 0.71 (0.60–0.82) 0.57 (0.43–0.71)
IL-18/uCr 0.63 (0.51–0.74) 0.72 (0.57–0.87) 0.58 (0.47–0.70) 0.54 (0.41–0.68)
KIM-1/uCr 0.62 (0.51–0.73) 0.72 (0.57–0.87) 0.66 (0.55–0.77) 0.58 (0.45–0.71)
Abbreviations: AKI, acute kidney injury; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C; eGFR, estimated glomerular
filtration rate; GGT, g-glutamyltranspeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary creatinine.
n=total number in category. Square brackets show number of patients with AKI.
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increased the power of this study. This was justified on the
basis that in the EARLYARF trial, no difference between
placebo and EPO was observed for the development of
dialysis (P¼ 0.72), death in 7 days (P¼ 0.36), or develop-
ment of AKI in 48 h (P¼ 0.88). As patients were triaged using
the first urine sample, only results based on outcomes
following the first sample could be affected by the presence of
EPO (that is, AKIN48, RIFLE24, need for dialysis, and
death). Nevertheless, we analyzed the data in Tables 3 and 4
and compared AUCs for the cohort including and excluding
patients who received EPO. No significant difference between
AUC was observed (data available in Supplementary Tables
S8 and S9 online).
A further limitation of the study is that for some patients,
B20%, the putative time of insult could not be deter-
mined accurately (within 1 h). This was primarily the sepsis
cohort for whom the onset of illness was considered as the
putative time of insult and depended on close inspection of
clinical notes pertaining to self-reporting of symptoms.
However, given that this uncertainty would add ‘noise’ to
the time from insult data and given the patterns that were
observed, we believe that our conclusions regarding the time
dependence of AUCs are not weakened by this limitation.
A comparison with myocardial ischemia suggests that
biomarkers of renal injury should be validated against other
markers of injury and/or against hard outcomes, such as
dialysis and death. All biomarkers were predictive of death
with the exception of KIM-1. All biomarkers were predictive
of dialysis. There are plausible mechanisms for participation
of all these biomarkers in renal injury, although the
mechanisms are less specific for pre-formed than for induced
biomarkers.29 Although this is presently the largest study of
multiple biomarkers, there were insufficient participants to
assess which biomarker best predicted death or dialysis.
Stratification for time and eGFR reduces power. Further
studies with hard outcomes are required to assess the viability
of these and other biomarkers as alternatives to surrogate
markers of function. Smaller studies should report dialysis
and death to enable later inclusion in meta-analyses.30
In conclusion, on admission to the ICU, both pre-formed
and upregulated urinary biomarkers performed more poorly
than expected. The performance of all biomarkers was
improved by stratification for time of collection with respect
to renal insult and for baseline renal function before injury.
The high negative-predictive value observed for all urinary
biomarkers can guide management; however, the absence of a
high positive-predictive value impedes triaging to interven-
tion in this very heterogeneous population. Future trials
should choose populations made homogeneous by a window
representing a narrow time of injury and of baseline renal
function appropriate for the triaging biomarker(s) and the
presumed mechanism of intervention.
MATERIALS AND METHODS
This prospective observational study was a planned component of the
EARLYARF randomized controlled trial of high-dose EPO in AKI of
consecutive patients who met the inclusion criteria in two large general
ICUs in two regional centers.16 This study was approved by the
multiregional ethics committee of New Zealand (MEC/050020029) and
registered under the Australian New Zealand Clinical Trials Registry
(ACTRN012606000032550, http://www.actr.org.au). Inclusion/exclu-
sion criteria, consent procedures, sample collection, and details of
analysis for GGT, AP, CysC, and creatinine have been detailed
elsewhere.16 In brief, eligible patients on entry to the ICU were all
adults expected to remain in the ICU for 424 h, survive 472 h, had
not experienced a threefold or greater increase in creatinine on entry,
were not anuric, on renal replacement therapy or assessed to need renal
replacement therapy within 48 h, did not have obvious hematuria,
rhabdomyolysis, myoglobinuria, or polycythemia, and were not
receiving chemotherapy. Urine samples were stored at 801C until
batch analysis for KIM-1, IL-18, or NGAL. Investigators blinded to
patients’ clinical characteristics performed all analyses. Urinary
biomarker concentrations were indexed to the urinary creatinine
concentration in the same sample. As EPO had no effect on outcome,
this analysis includes patients in both the observation and the
intervention arms.16 All biomarkers were measured on entry to the
ICU, and at 12 and 24 h after entry. Additional measurements for AP,
GGT, and CysC were made daily for 7 days. Urinary GGT, AP, CysC,
and creatinine were assayed as described previously.16 PCr was
measured on entry to the ICU, at 12, 24 h after entry, and daily for
7 days. Baseline creatinine was determined as described previously.16 In
brief, 51% of patients had a PCr before ICU admission; for the
remainder, the lowest of the on-admission creatinine or final ICU
creatinine was used. A similar approach has been shown to be more
accurate than using the Modification of Diet in Renal Disease equation
with the same assumed GFR to back-calculate a baseline creatinine.14
Baseline creatinine was used to calculate baseline eGFR using the
modification of diet in renal disease formula31 for stratification of
patients according to baseline renal function. We initially stratified
patients into four groups analogous to the study by McIlroy et al.,18
and then more simply into two groups with a baseline GFRo60 ml/
min (equivalent to chronic kidney disease) and those with GFR
X60 ml/min. We also stratified patients into one of four groups
according to time after probable renal insult on entry, namelyo6 h,
6 to o12 h, 12 to o36 h, and X36 h. Stratification by time was
determined by chart review of all patients as described previously, in
which the time of probable insult was known for some (cardiac
arrests, trauma, cardiopulmonary bypass), and estimated for the
remainder.16 In considering AKI on entry or within 48 h, the insult
was assumed to occur before entry to the ICU for all patients.
AKI on entry was defined as an increase in pCr 40.3 mg/dl
(26.4 mmol/l) or 50% above baseline pCr of the first sample in the
ICU.32 For analysis of biomarker predictive performance, patients
with AKI on entry were excluded and AKI determined using: (1) an
increase in pCr above baseline of at least 0.3 mg/dl (26.4 mmol/l) or
50% within 48 h of admission (AKIN48),32 and (2) an increase in
pCr of at least 50% above baseline sustained for X24 h within 7 days
of admission (RIFLE24).33 The ability of biomarkers on entry to the
ICU to predict dialysis or mortality within 7 days was also analyzed.
KIM-1 was measured using microsphere-based Luminex xMAP
technology (Luminex, Austin, TX), with polyclonal antibodies raised
against the human KIM-1 ectodomain as described previously.34,35
The lowest limit of detection for this assay is 4.4 pg/ml. The inter-
assay and intra-assay variability was o20%. NGAL was measured
using the NGAL ELISA (enzyme-linked immunosorbent assay) Kit
036 (AntibodyShop, Grusbakken, Denmark). Coefficients of inter-
assay and intra-assay variation for urine and plasma NGAL were
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5–10%. IL-18 was measured using a human IL-18 ELISA kit (Medical
and Biological Laboratories, Nagoya, Japan), which specifically
detects the mature form of IL-18.36 Coefficients of inter-assay and
intra-assay variation for IL-18 were 5–10% corresponding to that
reported by the manufacturer.
Results are presented as means±s.d. and medians (interquartile
range). All variables displayed extreme non-Gaussian distributions.
Therefore, a non-parametric test (Spearman’s) was used to assess the
correlation. Diagnostic and prognostic performance was assessed by
AUC. For a biomarker to be considered diagnostic or prognostic, it
must have an AUC significantly 40.5. An AUC of 1 signifies a
biomarker with perfect sensitivity and specificity. The method of
DeLong et al.37 was used to compare the AUCs of correlated receiver
operator characteristic curves (AUCs for biomarkers for the same
outcome on the same patients). To assess for independence of
biomarkers with mortality outcomes, a logistic regression model was
constructed with log-transformed biomarkers and covariates.
Statistical software used were SPSS 16.0 (SPSS, Chicago, IL),
GraphPad Prism 5.0a for Mac OS (GraphPad Software, San Diego,
CA), and Matlab 2009b (MathWorks, Natick, MA). Po0.05 was
considered significant. All confidence intervals presented are 95%.
Contour plots were constructed using Matlab contourf.
DISCLOSURE
Abbott Diagnostics has signed an exclusive licensing agreement with
the Cincinnati Children’s Hospital (PD) for developing urine NGAL as a
biomarker of acute renal failure. JVB is a co-inventor on patents
involving KIM-1. CLE is a co-inventor on patents involving urine IL-18.
ZHE has received travel support from Inverness and Abbott.
ACKNOWLEDGMENTS
The EARLYARF study was supported by the Health Research Council
of New Zealand grant 05/131 (Early intervention in acute renal
failure). The analysis was supported by an Australia New Zealand
Society of Nephrology Infrastructure and Enabling grant. The
dedication of John Dean, Jill Robinson, Robyn Hutchison, and nursing
staff of Canterbury and Dunedin hospitals and the Canterbury Health
Laboratory is gratefully acknowledged.
SUPPLEMENTARY MATERIAL
Table S1b: Urinary biomarker concentration on entry.
Table S2: Correlations among urinary biomarkers on entry.
Table S3: ROC–AUC Evaluation of biomarker performance on entry.
Table S4: AUC for prediction of AKI and dialysis in patients without
AKI on entry.
Table S5: AKI stratified accoding to time after insult.
Table S6: AKI stratified according to eGFR.
Table S7: AUC for diagnosis of AKI accoding to time after insult and
eGFR.
Table S8: ROC–AUCs for Evaluation of biomarker performance on entry:
comparison of those who did and did not receive erythropoietin.
Table S9: AUCs for prediction of AKI and dialysis in patients without
AKI on entry: comparison of those who did and did not receive
erythropoietin.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Han WK, Bailly V, Abichandani R et al. Kidney Injury Molecule-1 (KIM-1): a
novel biomarker for human renal proximal tubule injury. Kidney Int 2002;
62: 237–244.
2. Westhuyzen J, Endre ZH, Reece G et al. Measurement of tubular
enzymuria facilitates early detection of acute renal impairment in the
intensive care unit. Nephrol Dial Transplant 2003; 18: 543–551.
3. Parikh CR, Abraham E, Ancukiewicz M et al. Urine IL-18 is an early
diagnostic marker for acute kidney injury and predicts mortality in the
intensive care unit. J Am Soc Nephrol 2005; 16: 3046–3052.
4. Han WK, Wagener G, Zhu Y et al. Urinary biomarkers in the early detection
of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4:
873–882.
5. Nickolas TL, O’Rourke MJ, Yang J et al. Sensitivity and specificity of a
single emergency department measurement of urinary neutrophil
gelatinase-associated lipocalin for diagnosing acute kidney injury.
Ann Intern Med 2008; 148: 810–819.
6. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker for acute renal injury after cardiac
surgery. Lancet 2005; 365: 1231–1238.
7. Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for
kidney injury biomarker studies? Nephrol Dial Transplant 2009; 24: 3263–3265.
8. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005;
365: 417–430.
9. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal
failure: from advocacy to consensus and validation of the RIFLE criteria.
Intensive Care Med 2007; 33: 409–413.
10. Mehta RL. Fluid balance and acute kidney injury: the missing link for
predicting adverse outcomes? Nat Clin Pract Nephrol 2009; 5: 10–11.
11. Pickering JW, Frampton CM, Endre ZH. Evaluation of trial outcomes in
acute kidney injury by creatinine modeling. Clin J Am Soc Nephrol 2009; 4:
1705–1715.
12. Goldstein SL, Devarajan P. Progression from acute kidney injury to
chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis
2008; 15: 278–283.
13. Bagshaw SM, Uchino S, Cruz D et al. A comparison of observed versus
estimated baseline creatinine for determination of RIFLE class in
patients with acute kidney injury. Nephrol Dial Transplant 2009; 24:
2739–2751.
14. Pickering JW, Endre ZH. Back-calculating baseline creatinine with MDRD
misclassifies acute kidney injury in the intensive care unit. Clin J Am Soc
Nephrol 2010; 5: 1165–1173.
15. Siew E, Ware L, Gebretsadik T et al. Urine neutrophil gelatinase-associated
lipocalin moderately predicts acute kidney injury in critically ill adults.
J Am Soc Nephrol 2009; 20: 1823–1832.
16. Endre ZH, Walker RJ, Pickering JW et al. Early intervention with
erythropoietin does not affect the outcome of acute kidney injury (the
EARLYARF trial). Kidney Int 2010; 77: 1020–1030.
17. Haase M, Bellomo R, Devarajan P et al. Accuracy of neutrophil gelatinase-
associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney
injury: a systematic review and meta-analysis. Am J Kid Dis 2009; 54:
1012–1024.
18. McIlroy D, Wagener G, Lee H. Neutrophil gelatinase-associated lipocalin and
acute kidney injury after cardiac surgery: the effect of baseline renal function
on diagnostic performance. Clin J Am Soc Nephrol 2010; 5: 211–219.
19. Coca SG, Yalavarthy R, Concato J et al. Biomarkers for the diagnosis and
risk stratification of acute kidney injury: a systematic review. Kidney Int
2008; 73: 1008–1016.
20. Nejat M, Pickering JW, Walker RJ et al. Rapid detection of acute kidney
injury by plasma cystatin C in the intensive care unit. Nephrol Dial
Transplant 2010; 25: 3283–3289.
21. Nejat M, Pickering JW, Walker RJ et al. Urinary cystatin C is diagnostic of
acute kidney injury and sepsis, and prognostic of mortality in the
intensive care unit. Crit Care 2010; 14: R85.
22. Liang X-L, Liu S-X, Chen Y-H et al. Combination of urinary kidney injury
molecule-1 and interleukin-18 as early biomarker for the diagnosis and
progressive assessment of acute kidney injury following cardiopulmonary
bypass surgery: a prospective nested case–control study. Biomarkers
2010; 15: 332–339.
23. Han WK, Waikar SS, Johnson A; et al. Urinary biomarkers in the early
diagnosis of acute kidney injury. Kidney Int 2008; 73: 863–869.
24. Siew ED, Ikizler TA, Gebretsadik T et al. Elevated urinary IL-18 levels at the
time of ICU admission predict adverse clinical outcomes. Clin J Am Soc
Nephrol 2010; 5: 1497–1505.
25. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinase-
associated lipocalin reflects the severity of renal impairment in subjects
affected by chronic kidney disease. Kidney Blood Press Res 2008; 31:
255–258.
26. Pickering JW, Endre ZH. Secondary prevention of acute kidney injury.
Curr Opin Crit Care 2009; 15: 488–497.
27. Siew ED, Matheny ME, Ikizler TA et al. Commonly used surrogates for
baseline renal function affect the classification and prognosis of acute
kidney injury. Kidney Int 2010; 77: 536–542.
1128 Kidney International (2011) 79, 1119–1130
or ig ina l a r t i c l e ZH Endre et al.: Biomarker performance in AKI
28. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary
biomarkers to creatinine during changes in glomerular filtration rate.
Kidney Int 2010; 78: 486–494.
29. Mehta RL. Timed and targeted therapy for acute kidney injury: a glimpse
of the future. Kidney Int 2010; 77: 947.
30. Endre ZH, Pickering JW. Outcome definitions in non-dialysis intervention
and prevention trials in acute kidney injury (AKI). Nephrol Dial Transplant
2010; 25: 107–118.
31. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Ann Intern Med 1999; 130: 461–470.
32. Mehta RL, Kellum JA, Shah SV, et al., for the Acute Kidney Injury Network.
Acute Kidney Injury Network: report of an initiative to improve outcomes
in acute kidney injury. Crit Care 2007; 11: R31.
33. Bellomo R, Ronco C, Kellum JA, et al., for the Acute Dialysis Quality
Initiative workgroup. Acute renal failure—definition, outcome measures,
animal models, fluid therapy and information technology needs: the
Second International Consensus Conference of the Acute Dialysis Quality
Initiative (ADQI) Group. Crit Care 2004; 8: R204–R212.
34. Liangos O, Perianayagam MC, Vaidya VS et al. Urinary N-acetyl-beta-(D)-
glucosaminidase activity and kidney injury molecule-1 level are
associated with adverse outcomes in acute renal failure. J Am Soc Nephrol
2007; 18: 904–912.
35. Vaidya VS, Waikar SS, Ferguson MA et al. Urinary biomarkers for sensitive
and specific detection of acute kidney injury in humans. Clin Transl Sci
2008; 1: 200.
36. Shibata M, Hirota M, Nozawa F et al. Increased concentrations of plasma
IL-18 in patients with hepatic dysfunction after hepatectomy. Cytokine
2000; 12: 1526–1530.
37. DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under 2
or more correlated receiver operating characteristic curves—a nonpara-
metric approach. Biometrics 1988; 44: 837–845.
Appendix
AUC for diagnosis of AKI according to time after insult and eGFR
o6h 6 to o12h 12 to o36h X36h
eGFR (ml/min) Time from insult n=24 [3] n=40 [4] n=12 [8] n=20 [12]
o60 GGT/uCr 0.41 (0.08–0.75) 0.26 (0.04–0.49) 0.91 (0.73–1) 0.48 (0.21–0.74)
AP/uCr 0.17 (0–0.38) 0.19 (0.01–0.37) 0.62 (0.29–0.96) 0.40 (0.13–0.66)
CysC/uCr 0.69 (0.34–1) 0.65 (0.35–0.96) 0.88 (0.67–1) 0.44 (0.17–0.70)
NGAL/uCr 0.45 (0.10–0.80) 0.39 (0.07–0.7) 0.85 (0.58–1) 0.58 (0.32–0.84)
IL-18/uCr 0.62 (0.26–0.98) 0.61 (0.30–0.92) 0.94 (0.80–1) 0.41 (0.14–0.67)
KIM-1/uCr 0.73 (0.39–1) 0.43 (0.14–0.72) 0.66 (0.33–0.98) 0.65 (0.40–0.89)
n=64 [14] n=27 [9] n=43 [16] n=38 [17]
60–o90 GGT/uCr 0.70 (0.53–0.86) 0.69 (0.46–0.91) 0.67 (0.50–0.84) 0.48 (0.30–0.67)
AP/uCr 0.65 (0.47–0.82) 0.55 (0.31–0.79) 0.38 (0.21–0.55) 0.41 (0.23–0.59)
CysC/uCr 0.63 (0.46–0.81) 0.65 (0.42–0.88) 0.59 (0.41–0.77) 0.40 (0.22–0.58)
NGAL/uCr 0.58 (0.40–0.76) 0.60 (0.35–0.85) 0.72 (0.54–0.89) 0.52 (0.33–0.72)
IL-18/uCr 0.61 (0.44–0.79) 0.73 (0.52–0.95) 0.58 (0.40–0.76) 0.43 (0.24–0.61)
KIM-1/uCr 0.75 (0.59–0.91) 0.66 (0.43–0.89) 0.72 (0.56–0.89) 0.44 (0.26–0.63)
n=56 [10] n=35 [5] n=35 [14] n=32 [5]
90–o120 GGT/uCr 0.87 (0.73–1) 0.85 (0.64–1) 0.47 (0.28–0.66) 0.70 (0.42–0.97)
AP/uCr 0.64 (0.44–0.84) 0.60 (0.32–0.88) 0.38 (0.20–0.56) 0.29 (0.07–0.51)
CysC/uCr 0.83 (0.67–0.99) 0.89 (0.70–1) 0.74 (0.57–0.91) 0.64 (0.36–0.93)
NGAL/uCr 0.82 (0.65–1) 0.64 (0.33–0.95) 0.73 (0.55–0.91) 0.52 (0.23–0.80)
IL-18/uCr 0.71 (0.52–0.91) 0.78 (0.52–1) 0.66 (0.47–0.84) 0.52 (0.24–0.80)
KIM-1/uCr 0.53 (0.33–0.74) 0.85 (0.63–1) 0.59 (0.40–0.78) 0.73 (0.47–1)
n=33 [10] n=21 [3] n=22 [11] n=20 [6]
X120 GGT/uCr 0.67 (0.45–0.88) 0.78 (0.45–1) 0.54 (0.29–0.78) 0.61 (0.32–0.89)
AP/uCr 0.65 (0.43–0.86) 0.63 (0.26–1) 0.32 (0.10–0.55) 0.40 (0.13–0.67)
CysC/uCr 0.60 (0.38–0.81) 0.75 (0.40–1) 0.64 (0.40–0.87) 0.76 (0.50–1)
NGAL/uCr 0.66 (0.43–0.88) 0.72 (0.37–1) 0.68 (0.45–0.91) 0.63 (0.33–0.94)
IL-18/uCr 0.54 (0.32–0.76) 0.54 (0.17–0.9) 0.45 (0.21–0.7) 0.64 (0.36–0.92)
KIM-1/uCr 0.46 (0.24–0.67) 0.61 (0.24–0.98) 0.64 (0.40–0.87) 0.62 (0.34–0.90)
Abbreviations: AKI, acute kidney injury; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C; eGFR, estimated glomerular
filtration rate; GGT, g-glutamyltranspeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary creatinine.
n=total number in category. Square brackets show number of patients with AKI.
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AUC for prediction of AKI in patients without AKI on entry according to time after insult and eGFR
o6 h 6 to o12h 12 to o36 h X36h
eGFR (ml/min) Time from insult n=21 [5] n=36 [10] n=4 [2] n=8 [3]
o60 GGT/uCr 0.96 (0.84–1) 0.81 (0.64–0.99) 0.50 (0–1) 0.93 (0.71–1)
AP/uCr 0.99 (0.92–1) 0.71 (0.51–0.91) 0.50 (0–1) 0.67 (0.25–1)
CysC/uCr 0.76 (0.49–1) 0.59 (0.38–0.81) 0.38 (0–0.99) 1 (1–1)
NGAL/uCr 0.76 (0.49–1) 0.65 (0.4–0.89) 0.50 (0–1) 0.87 (0.56–1)
IL-18/uCr 0.57 (0.27–0.87) 0.75 (0.56–0.94) 0.50 (0–1) 0.67 (0.25–1)
KIM-1/uCr 0.81 (0.57–1.1) 0.64 (0.43–0.85) 0.50 (0–1) 0.33 (0–0.73)
n=50 [12] n=18 [4] n=27 [3] n=21 [6]
60–o90 GGT/uCr 0.29 (0.13–0.44) 0.80 (0.52–1) 0.72 (0.38–1) 0.50 (0.22–0.78)
AP/uCr 0.38 (0.21–0.56) 0.52 (0.19–0.85) 0.43 (0.09–0.77) 0.58 (0.3–0.86)
CysC/uCr 0.41 (0.23–0.59) 0.61 (0.27–0.94) 0.54 (0.18–0.90) 0.89 (0.70–1)
NGAL/uCr 0.43 (0.25–0.61) 0.46 (0.03–0.90) 0.70 (0.27–1.1) 0.64 (0.34–0.94)
IL-18/uCr 0.31 (0.15–0.47) 0.64 (0.31–0.97) 0.25 (0–0.50) 0.86 (0.65–1)
KIM-1/uCr 0.41 (0.23–0.59) 0.61 (0.27–0.94) 0.24 (0–0.48) 0.51 (0.23–0.79)
n=46 [10] n=30 [4] n=25 [4] n=27 [8]
90–o120 GGT/uCr 0.52 (0.31–0.73) 0.57 (0.25–0.88) 0.51 (0.20–0.83) 0.39 (0.17–0.62)
AP/uCr 0.61 (0.40–0.82) 0.64 (0.33–0.96) 0.42 (0.12–0.71) 0.46 (0.22–0.7)
CysC/uCr 0.47 (0.27–0.67) 0.55 (0.23–0.86) 0.52 (0.16–0.87) 0.68 (0.44–0.91)
NGAL/uCr 0.61 (0.40–0.82) 0.47 (0.17–0.77) 0.50 (0.18–0.82) 0.56 (0.31–0.8)
IL-18/uCr 0.35 (0.17–0.53) 0.56 (0.24–0.88) 0.67 (0.35–0.98) 0.84 (0.65–1)
KIM-1/uCr 0.62 (0.41–0.82) 0.58 (0.26–0.90) 0.59 (0.27–0.91) 0.71 (0.48–0.94)
n=23 [5] n=18 [2] n=11 [2] n=14 [2]
X120 GGT/uCr 0.54 (0.25–0.84) 0.47 (0.041–0.9) 0.61 (0.14–1) 0.58 (0.13–1)
AP/uCr 0.72 (0.44–1) 0.44 (0.02–0.86) 0.39 (0–0.82) 0.42 (0–0.84)
CysC/uCr 0.36 (0.09–0.62) 0.33 (0–0.71) 0.42 (0–0.86) 0.32 (0–0.7)
NGAL/uCr 0.48 (0.19–0.77) 0.22 (0–0.51) 0.67 (0.21–1) 0.27 (0.19–0.74)
IL-18/uCr 0.46 (0.17–0.74) 0.47 (0.04–0.9) 0.50 (0.04–0.96) 0.52 (0.07–0.97)
KIM-1/uCr 0.46 (0.17–0.74) 0.41 (0–0.81) 0.39 (0.04–0.82) 0.083 (0–0.25)
Abbreviations: AKI, acute kidney injury; AP, alkaline phosphatase; AUC, area under the receiver operator characteristic curve; CysC, cystatin C; eGFR, estimated glomerular
filtration rate; GGT, g-glutamyltranspeptidase; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin; uCr, urinary creatinine.
n=total number in category. Square brackets show number of patients with AKI.
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